92.9% Think Polymorphism and Crystallisation is the Greatest Challenge They Face
We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.
Polymorphism and crystallisation are considered to be one of the most significant and demanding areas of pharmaceutical development. New discoveries have the potential to either give organisations a share of a crowded market place to great financial and reputational benefit or have hugely damaging repercussions, depending on at what stage the alternative crystallisation formation was discovered.
However, with the swift leaps and bounds in technology development and quality by design processes, organisations are also faced with the challenge of keeping up to date with the latest research in order to stay at the forefront of the industry, as well as improve safety, best practice and the efficacy of drugs.
Have Your Say
Rate this feature and give us your feedback in the comments section below
TO READ THE FULL STORY
Please note: That all fields marked with an asterisk (*) are required.